Research Synthesis: Caloric Restriction Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either remove the Jorgensen 2026 veterinary study from the active evidence tables and cross-source tension list, or move it to a clearly demarcated 'Animal/Preclinical Context' section that is never pooled with human outcome data. Its P=0.04 statistic should not appear adjacent to human RCTs in the main Results.
2. Revert Houston 2018 to the bundle-coded direction ('unclear') unless the manuscript provides verbatim text from the bundle excerpt that supports a positive direction. The current 'reviewer-reconciled direction=positive' line is a silent override of the bundle.
3. Replace the generic 'a source-reported estimate' tokens in the Results, Key Findings, and Evidence Snapshot with the actual p-values, mean differences, and confidence intervals present in the bundle excerpts (e.g., Reljic 2022 p=0.001 for CRP; Reljic 2021 MetS z-score p=0.003 and p<0.001; Lyngbaek 2024 FM% mean differences with 95% CIs; Romashkan 2016 organ-system p=0.02/0.02/0.002; Houston 2025 body weight 6.4±5.4 kg and ΔTEE -47±353 kcal/d; Houston 2018 OR 0.84 [0.71-0.99]; Evans 2023 FI-E 0.0130 [0.0104-0.0156]).
4. Remove the WHO/Cruz-Jentoft/Cesari/Studenski/Perera boundary-condition claims from the Cross-Domain Synthesis, or move them to a 'proposed anchors' subsection that is clearly distinguished from source-traced claims. The cited thresholds are not present in the source bundle and therefore fail traceability.
5. Consolidate the Key Findings section with the Evidence Snapshot to remove duplication, or restructure Key Findings to surface only the integrative takeaways that are not already in the table.

Major issues

• The manuscript includes a veterinary/preclinical study (Jorgensen 2026, cats with diabetes) within a clinical synthesis and reports its statistic (P = 0.04) as load-bearing evidence alongside human RCTs. Even though the author flags it as excluded from human aggregates, its substantive discussion and inclusion in tables and cross-source tension maps blurs the preclinical-to-clinical boundary and risks an unsupported mechanistic-to-clinical bridge.
• The 'Source-direction reconciliation (Houston 2018 [bundle:36]): reviewer-reconciled direction=positive is used consistently' admission without further justification is an integrity concern: the bundle's effect_direction is 'unclear', but the manuscript overrides it to 'positive' for narrative use. This reviewer override must be either (a) reverted to the bundle-coded 'unclear' or (b) explicitly justified with quoted source text showing the positive direction; as written, it constitutes an undocumented direction rewrite that affects load-bearing claims.
• Several exact statistics are reported in the Evidence Landscape and Key Findings with phrasing like 'a source-reported estimate' instead of the actual p-value or effect size. Where bundle excerpts contain verifiable numerics (e.g., Reljic 2022: CRP p=0.001; Houston 2025: body weight 6.4±5.4 kg; Lyngbaek 2024: FM% mean differences with 95% CIs; Romashkan 2016: within-CR organ-system p-values), the manuscript substitutes generic 'source-reported estimate' tokens, weakening numeric traceability at the gatekeeper tier.
• The 'Key Findings' section in the Results largely duplicates content already present in the Evidence Landscape and Evidence Snapshot tables, producing structural redundancy rather than new integration. This is bloat, not depth, and dilutes the synthesis.
• The 'Outcome-class note' in Results and the Cross-Domain Synthesis discuss WHO/Cruz-Jentoft/Cesari/Studenski thresholds, Perera 2006, and Redman 2009 metabolic adaptation as boundary anchors, but Perera 2006, Cesari 2009, Studenski 2011, Cruz-Jentoft 2019, and Redman 2009 (different from the bundle's Redman 2009 metabolic compensation paper? — verify) are not in the source bundle, so the cited thresholds lack bundle-traceable support.

Minor issues

• The 'Outcome-class key findings' list omits the lead sources cited in the Evidence Snapshot (Reljic 2021, Razny 2021) and reorders Weaver 2026 and Hwang 2020 without explanation, creating inconsistency between the two sections.
• The Frailty outcome is reported as n=3 in the Conclusion, n=3 in the Findings Map, and n=3 in the Results Summary, but the per-source direction table lists only 'unclear' across all three (Beavers 2022, Hsieh 2021, Evans 2023) — the manuscript should state explicitly that no coded direction in the frailty slice carries positive, negative, or mixed evidence.
• The Methods section states that 'Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates' but no pooled estimate is actually presented. Either the pooling criterion should be removed or a worked example should be shown.
• The Source Classification Map lists two sources (Weaver 2026 and Beavers 2021) with outcome=muscle_function and outcome=cardiometabolic respectively, but the Findings Map places Beavers 2021 under Cardiometabolic and Weaver 2026 under Muscle Function — these are consistent, but the abstract refers to 'Weaver 2026' as cardiometabolic-adjacent without explicitly noting its muscle-function classification.
• Reference bundle entries 'Hsu 2025' and 'Houston 2025' (corpus-sourced) and 'Kim 2025' and 'Weaver 2021' (corpus-sourced) carry 'source_type: corpus' and no PMID, so the claim that 31 of 37 sources carry p-values is partially inflated; the corpus-only entries should be counted separately in the verification accounting.

Reviewer note

This is a competent, gatekeeper-tier-structured research synthesis of 37 sources on caloric restriction effects, with explicit methods, a quantitative evidence index, a cross-domain synthesis section, and a bounded conclusion. The structural depth is real: outcome-class partitioning, directness coding, evidence tiers, and a load-bearing tension map are all present and clearly labeled. The bounded conclusion is honest and the limitations section materially constrains the claims. However, the manuscript has several issues that prevent acceptance. (1) The Houston 2018 direction override from 'unclear' to 'positive' is a silent reviewer reconciliation without verbatim source justification, which is an integrity-relevant issue at the gatekeeper tier. (2) The Jorgensen 2026 veterinary RCT sits inside a clinical synthesis and contributes a P-value to the active evidence tables, blurring the preclinical-to-clinical boundary even though it is tagged as excluded from human aggregates. (3) Several bundle-traceable exact statistics (e.g., Reljic 2022 p=0.001 for CRP, Romashkan 2016 organ-system p-values, Houston 2025 body-weight and TEE values, Houston 2018 OR 0.84) are masked behind 'a source-reported estimate' tokens, weakening numeric traceability — a core gatekeeper requirement. (4) The cross-domain synthesis invokes WHO, Cruz-Jentoft, Cesari, Studenski, and Perera thresholds that are not in the source bundle, so those boundary-condition claims are not source-traced. (5) The Key Findings section substantially duplicates the Evidence Snapshot. On the positive side, the limitations section is materially substantive (CALERIE 24-month follow-up, no mortality trials, single-source outcomes, narrow endpoint coverage, no incident frailty/hip fracture/mortality), the gaps are specific and actionable (P1 frailty direct-interventional gap, P2 cardiometabolic conflict-resolution gap, etc.), and the overall claim-evidence alignment is honest — the conclusion correctly does not support clinical actionability. The animal/preclinical separation and the boundary-condition framing are calibrated well. The fixable issues are bounded: revert the Houston 2018 direction, remove or quarantine the Jorgensen 2026 study, restore the masked exact statistics, drop or reframe the untraceable threshold citations, and consolidate the duplicate sections. None of these requires a scope reset, so the recommendation is revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: sparring_failed_primary_used

Prompt: reviewer-v12-grounded-integrity